JiangXi Tianxin Pharm Co Ltd

603235 · SHG · Consumer Defensive / Packaged Foods

23.72CNY-0.26 (-1.08%)

Price History

Full chart

Market Stats

Previous Close23.98

Open23.98

Day Range23.64 – 24.15

52-Week Range21.07 – 28.04

Volume336.83K

Market Cap11.36B

P/E (TTM)20.60

Forward P/E0.00

EPS1.26

Dividend Yield2.12%

Beta0.26

50-Day Avg24.36

200-Day Avg25.47

About

JiangXi Tianxin Pharmaceutical Co., Ltd. produces and sells vitamins in China. The company offers products of vitamin B6, vitamin B1, Vitamin B5, Vitamin D3, pyridoxine hydrochloride CD grade, thiamine nitrate DC grade, folic acid, biotin, ascorbyl palmitate, vitamin E 500, a-acetyl-"-butyrolactone, ABL, cholesterol, L-alanine, and vitamin D3 for use as bulk pharmaceutical chemicals, API, food additives, and feed additives, as well as in other fields. JiangXi Tianxin Pharmaceutical Co., Ltd. was founded in 2004 and is based in Leping, China.

Company Details

SectorConsumer Defensive
IndustryPackaged Foods
CEOMr. Xiaobing Yua
Employees2.89K
HeadquartersLeping Industrial Park, Leping, China, 333300, China
Websitehttps://www.txpharm.com

Leadership

Mr. Xiaobing YuaGM & Director · b. 1981
Mr. Xuelin LuoCFO & Financial Director · b. 1974
Mr. Yi DongBoard Secretary · b. 1988
Mr. Shengyang LiDeputy General Manager · b. 1981
Liang LiangAccounting Supervisor

Financials

Income Statement

Currency: CNY	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	2.30B	2.52B	2.30B	1.88B	2.21B	2.35B
Growth (%)	-	+9.50%	-8.63%	-18.34%	+17.35%	+6.18%
Cost of Revenue	1.05B	1.43B	1.45B	1.16B	1.28B	1.35B
Gross Profit	1.25B	1.09B	857.97M	720.28M	927.85M	992.23M
Gross Margin	54.28%	43.25%	37.23%	38.27%	42.01%	42.31%
Operating Expense	118.49M	163.74M	232.88M	253.36M	260.24M	302.87M
Operating Income	1.13B	927.23M	625.09M	466.92M	667.61M	689.36M
Operating Margin	49.14%	36.76%	27.12%	24.81%	30.23%	29.40%
EBITDA	-	-	859.80M	706.02M	928.41M	894.82M
EBITDA Margin	-	-	37.30%	37.51%	42.04%	38.16%
Net Income	887.09M	743.89M	622.12M	475.85M	651.22M	591.58M
Net Income Margin	38.51%	29.49%	26.99%	25.28%	29.49%	25.23%
R&D	49.36M	58.94M	89.46M	111.96M	103.82M	100.52M
R&D as % of Total Revenue	2.14%	2.34%	3.88%	5.95%	4.70%	4.29%
Interest Expense	13.06M	12.67M	6.93M	2.10M	2.48M	473.26K
Interest Expense % of Total Revenue	0.57%	0.50%	0.30%	0.11%	0.11%	0.02%

Balance Sheet

Currency: CNY	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	-	2.92B	2.95B	4.68B	5.09B	5.60B	6.19B
Total Liabilities	-	1.76B	1.04B	621.98M	857.21M	987.41M	1.27B
Total Equity	-	1.15B	1.91B	4.06B	4.23B	4.62B	4.92B
Cash	-	1.02B	717.08M	2.07B	2.31B	1.08B	1.57B

Cash Flow

Currency: CNY	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	1.16B	818.63M	606.61M	729.21M	499.66M	629.36M
Capital Expenditure	303.04M	215.50M	260.50M	535.60M	1.07B	580.68M
Free Cash Flow	860.63M	603.13M	346.11M	193.61M	-567.30M	48.68M
Dividends Paid	853.39M	878.47M	6.83M	312.42M	220.19M	304.82M
FCF to OCF	73.96%	73.68%	57.06%	26.55%	-113.54%	7.73%
Dividend Paid to FCF	99.16%	145.65%	1.97%	161.37%	-38.81%	626.16%

Earnings

Report Date	Sep 30, 2022	Dec 31, 2022	Apr 21, 2023
EPS Estimate	-	-	-
EPS Actual	0.34	0.16	0.25
Surprise	-	-	-
Timing	-	-	After-hours

Key Statistics & Ratios

Market Cap11.36B

Enterprise Value9.72B

Trailing P/E20.60

Forward P/E0.00

Price / Sales4.49

Price / Book2.21

EPS1.26

Book Value11.48

Revenue (TTM)2.53B

Gross Profit (TTM)1.00B

EBITDA833.51M

Profit Margin21.91%

Operating Margin29.38%

Return on Equity11.47%

Return on Assets6.35%

Shares Outstanding437.78M

Shares Float41.17M

Beta0.26

Dividend Yield2.12%

Dividend Rate0.55

Payout Ratio43.65%

Dividends

20261×

0.55Jul 1, 2026

20251×

0.68Jun 17, 2025

20241×

0.50Jun 26, 2024

20231×

0.71Jun 5, 2023